Pharma giant Novartis working on H7N9 vaccine

Swiss pharmaceuticals giant Novartis is researching a vaccine for the H7N9 strain of bird flu, its chief executive said Thursday, amid fears that the disease could mutate into a form that spreads among people.

In an interview with the Swiss daily Tagesanzeiger, Joe Jimenez said that Novartis had already analysed the virus' genetic codes, which have been published by .

Jimenez said that Novartis "would today be in a position to develop a vaccine for initial clinical trials within six to eight weeks".

"The need is theoretical for now," he added.

Since the discovery of the first cases several weeks ago in China, a total of 108 people have been confirmed as being infected with the H7N9 virus, of whom 22 have died, marking the first time the strain has claimed human lives.

Officials from the have underlined that the strain is therefore one of the deadliest of the many forms of flu carried by birds and posing various degrees of risk to humans.

On Wednesday, Taiwan recorded the first case outside China, in a man who had recently returned from working there.

There have been no recorded cases to human-to-human transmission, but the spectre of a form of the virus being able to jump between people has placed global health officials on alert.

Related Stories

H7N9 bird flu cases set to climb, but no pandemic: WHO

date Apr 03, 2013

The number of cases of H7N9 bird flu in China looks set to climb as experts identify previously unexplained infections, but a lack of human-to-human transmission means a pandemic is not on the cards, the World Health Organisation ...

Two in China first known deaths from H7N9 bird flu

date Mar 31, 2013

Two Shanghai men have died from a lesser-known type of bird flu in the first known human deaths from the strain, and Chinese authorities said Sunday that it wasn't clear how they were infected, but that there was no evidence ...

Recommended for you

Teva to lift bid for Mylan: report

date 3 hours ago

Israeli pharmaceutical giant Teva plans to increase its bid for rival Mylan and could announce the move as soon as this week, according to a US media report Monday.

Vaccine for West Nile Virus enters human clinical trials

date 8 hours ago

A clinical trial of a new investigational vaccine designed to protect against West Nile Virus infection will be sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes ...

FDA clears drug for leading form of cystic fibrosis

date Jul 02, 2015

Federal health officials have approved a new combination drug for the most common form of cystic fibrosis, the debilitating inherited disease that causes internal mucus buildup, lung infections and early death. But it will ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.